SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates

Phase 1 SQZ-AAC-HPV-101 Clinical Trial Resumed Following the Observation of a Confirmed Complete Response in the First Patient in the Lowest-Dose Cohort; Anticipate Data for the Highest-Dose Cohort in the Fourth Quarter of 2023SQZ® eAPC Phase 1/2 Trial Enrollment on Track; Anticipate Data for the Highest-Dose Monoth...

Related Keywords

Howard Bernstein ,Study Safety Committee ,Exchange Commission ,Company Quarterly Report On Form ,Biotechnologies Company ,Trial Resumed Following ,Confirmed Complete Response ,First Patient ,Lowest Dose Cohort ,Anticipate Data ,Highest Dose Cohort ,Fourth Quarter ,Interim Chief Executive Officer ,Recent Portfolio ,Enhanced Antigen Presenting Cell ,Activating Antigen Carriers ,Stage Programs ,Tolerizing Antigen Carriers ,Cell Squeeze ,Private Securities Litigation Reform Act ,Quarterly Report ,Annual Report ,Consolidated Statements ,